- Home
- OLPX vs GYRE Comparison
OLPX vs GYRE Comparison
Compare OLPX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLPX
- GYRE
- Stock Information
- Founded
- OLPX 2014
- GYRE 2002
- Country
- OLPX United States
- GYRE United States
- Employees
- OLPX N/A
- GYRE N/A
- Industry
- OLPX Package Goods/Cosmetics
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OLPX Consumer Discretionary
- GYRE Health Care
- Exchange
- OLPX Nasdaq
- GYRE Nasdaq
- Market Cap
- OLPX 1.0B
- GYRE 897.1M
- IPO Year
- OLPX 2021
- GYRE N/A
- Fundamental
- Price
- OLPX $1.50
- GYRE $7.23
- Analyst Decision
- OLPX Hold
- GYRE
- Analyst Count
- OLPX 4
- GYRE 0
- Target Price
- OLPX $1.88
- GYRE N/A
- AVG Volume (30 Days)
- OLPX 1.4M
- GYRE 164.0K
- Earning Date
- OLPX 08-05-2025
- GYRE 08-12-2025
- Dividend Yield
- OLPX N/A
- GYRE N/A
- EPS Growth
- OLPX N/A
- GYRE N/A
- EPS
- OLPX 0.02
- GYRE 0.02
- Revenue
- OLPX $420,742,000.00
- GYRE $100,643,000.00
- Revenue This Year
- OLPX $1.32
- GYRE $21.04
- Revenue Next Year
- OLPX $3.12
- GYRE $89.64
- P/E Ratio
- OLPX $81.78
- GYRE $88.77
- Revenue Growth
- OLPX N/A
- GYRE N/A
- 52 Week Low
- OLPX $1.01
- GYRE $6.11
- 52 Week High
- OLPX $2.77
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- OLPX 55.71
- GYRE 42.43
- Support Level
- OLPX $1.32
- GYRE $7.09
- Resistance Level
- OLPX $1.56
- GYRE $7.63
- Average True Range (ATR)
- OLPX 0.09
- GYRE 0.40
- MACD
- OLPX -0.01
- GYRE 0.00
- Stochastic Oscillator
- OLPX 57.14
- GYRE 15.38
About OLPX Olaplex Holdings Inc.
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.